Ventilatory dysfunction precedes pulmonary vascular changes monocrotaline-treated rats monocrotaline MCT pulmonary hypertension profound increase lung resistance RL decrease lung compliance airway/lung dysfunction evolution MCT-induced pulmonary vascular disease important temporal relationship development pulmonary hypertension ventilatory function MCT-treated rats issue young Sprague-Dawley rats groups control MCT rat single subcutaneous injection MCT mg/kg wk functional study wk MCT significant increases RL alveolar wall thickness significant decrease carbon monoxide capacity DLCO Medial thickness pulmonary arteries microns OD right ventricular hypertrophy wk post-MCT Coincident right ventricular hypertrophy wk post-MCT DLCO alveolar wall thickness lung dry weight Pressure-volume curves air-filled saline-filled lungs marked rightward shifts wk MCT administration wk data MCT-induced alterations airway/lung function pulmonary vasculature implicate airway/lung dysfunctions later development pulmonary vascular abnormalities 